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Abstract
PURPOSE: The aims of the present work were to investigate the in vitro and in vivo antiangiogenic effects of chronic
temozolomide treatment on various glioma models and to demonstrate whether bevacizumab (Avastin) increased
the therapeutic benefits contributed by temozolomide in glioma. EXPERIMENTAL DESIGN: The expression levels
of various antiangiogenic factors in four glioma cell lines were evaluated after chronic in vitro treatment with
temozolomide by Western blot. Proliferation and migration assays were performed on human endothelial cells
incubated with supernatants of glioma cells treated with and without temozolomide. Orthotopic glioma models
were used to evaluate the antiangiogenic effects of temozolomide in vivo and the therapeutic benefits of different
temozolomide treatment schedules used alone or in combination with bevacizumab. RESULTS: Temozolomide,
a proautophagic and proapoptotic drug, decreased the expression levels of HIF-1α, ID-1, ID-2, and cMyc in the
glioma models investigated, all of which playing major roles in angiogenesis and the switch to hypoxic metabo-
lism. These changes could be, at least partly, responsible for the impairment of angiogenesis observed in vitro and
in vivo. Moreover, combining bevacizumab with temozolomide increased the survival of glioma-bearing mice in
comparison to each compound administered alone. CONCLUSIONS: In addition to the numerous mechanisms
of action already identified for temozolomide, we report here that it also exerts antitumor effects by impairing an-
giogenic processes. We further emphasize that bevacizumab, which is an antiangiogenic drug with a different
mechanism of action, could be useful in combination with temozolomide to increase the latter’s therapeutic bene-
fit in glioma patients.
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Introduction
Glioblastoma (GBM) is the most frequent and most malignant human
brain tumor [1,2]. Prognosis remains very poor because GBM cells dra-
matically invade brain parenchyma and they are naturally resistant to
apoptosis and thus to most cytotoxic drugs and to radiotherapy [3,4].
The treatment of GBMs requires a multidisciplinary approach that
takes the presently incurable nature of the disease into consideration
and normally includes surgery, radiotherapy, and chemotherapy [5]. Al-
though temozolomide (TMZ; Temodal) does not cure GBM patients,
it significantly improves GBM patient survival and quality of life [6]
even of patients harboring 9p or 10q chromosomal deletions which are
associated with dismal prognosis [7]. Temozolomide exerts its antitumor
effects through several distinct mechanisms of action. Temozolomide
increases GBM sensitivity to radiotherapy [8] most effectively in O6-
methylguanine-DNA methyltransferase (MGMT)–negative GBMs by
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increasing the degree of radiation-induced double-strand DNA dam-
age [9]. Part of TMZ’s cytotoxicity toward GBM cells is exerted
through proautophagic [10] and/or apoptotic [11] processes. Hegi
et al. [12] showed that patients who had GBMs that contained a
methylated MGMT promoter benefited from TMZ, whereas those
who did not were less responsive. In addition to MGMT [12,13],
other determinants of sensitivity of gliomas to TMZ are p53 status,
proliferation rate, and double-strand breaks (DSBs) repair [11,13].
The O6-methylguanine adducts formed by TMZ also lead to inhibi-
tion of the NF-κB signaling pathway [14], which is constitutively
activated in GBMs and contributes to their resistance to cytotoxic
drugs and to radiotherapy [3]. The Akt signaling pathway is also di-
rectly involved in GBM cell resistance to apoptosis [3,15], and Akt
activation suppresses TMZ-induced Chk2 activation and G2 arrest,
with the overriding effect being protection from TMZ-induced cyto-
toxicity [16]. It has also been suggested that TMZ-induced anti-
GBM effects could relate to antiangiogenic effects [17–20].
Apart from all these detrimental effects of TMZ against GBM cells
leading to beneficial therapeutic consequences for GBM patients, the
compound can also be associated with positive effects on GBM cells.
By impairing these TMZ-associated positive effects on GBM cells,
at least partly, it would be possible to further increase the therapeutic
benefits contributed by this drug to GBM patients. For example, TMZ
can induce an autophagy-associated ATP surge that protects glioma
cells and may contribute to drug resistance [21]. Fisher et al. [22] have
shown that treatment of human GBM cells with TMZ activates stress
mechanisms that include the angiogenesis-inducing proteins notably
hypoxia-inducible factors such as HIF-1α and vascular endothelial
growth factor (VEGF), leading therefore to proangiogenic signals
[22]. This is in contrast to previous antiangiogenic effects reported
for the drug [17–20]. We recently demonstrated that TMZ increases
galectin-1 expression in GBM cells both in vitro and in vivo [23,24].
Galectin-1 is a hypoxia-regulated protein [25] that exerts potent pro-
angiogenic effects [26] and controls GBM cell migration [27]. How-
ever, reducing galectin-1 expression in these cells by siRNA increases
the antitumor effects of various chemotherapeutic agents, in particular,
TMZ, both in vitro and in vivo [23,24]. We have shown that decreas-
ing galectin-1 expression in GBM [24] models markedly impairs tumor
neoangiogenesis through impairment of ORP150 expression, which
leads to defects in VEGF maturation (and thus secretion) and ulti-
mately increases the therapeutic benefits contributed by TMZ [24].
Taken together, these data strongly suggest that impairing VEGF expres-
sion in GBM would improve the therapeutic benefits of TMZ [24].
The aim of the present work was to investigate the in vitro and
in vivo effects of chronic TMZ treatment on various GBM models and
to identify those antiangiogenic pathways activated by the compound.
Accordingly, the effects of TMZ on HIF-1α, inhibitor of differentiation
factors ID-1 and ID-2 and the oncogene cMyc have been investigated.
Additionally, the studies reported here aimed to demonstrate whether
bevacizumab (Avastin; a humanizedmonoclonal antibody against VEGF,
which may have activity in recurrent malignant gliomas [28]) increases
the therapeutic benefits of TMZ in GBM models.
Materials and Methods
Cell Cultures and Compounds
The Hs683 (ATCC code HTB-138), U87 (ATCC code HTB-14),
U373 (ATCC code HTB-17) and T98G (ATCC code CRL-1690)
human GBM cell lines were obtained from the American Type Cul-
ture Collection (ATCC; Manassas, VA) and maintained in our labora-
tory as detailed previously [23,24,27].
Primary human umbilical vein endothelium cells (HUVECs) were
obtained from umbilical cords sampled at the Erasmus University Hos-
pital, Brussels, Belgium. The cells were isolated by collagenase treatment
and were grown in endothelial cell growth medium EGM-2 MV
BulletKit from Lonza (Verviers, Belgium). Human umbilical vein endo-
thelium cell cultures were used between passages 5 and 10. Two distinct
batches of HUVECs designated CH14 and HTG06 were prepared.
Temozolomide was obtained from Schering-Plough (Brussels, Bel-
gium). Bevacizumab was obtained from Roche (Brussels, Belgium).
In Vitro Overall Growth Determination
Overall cell growth was assessed using the 3-[4,5-dimethylthiazol-
2yl]-diphenyltetrazolium bromide (MTT) colorimetric assay (Sigma,
Bornem, Belgium), as detailed elsewhere [23,29]. All determinations
were carried out in sextuplicate. Control conditions consisted of en-
dothelial cells cultured with endothelial cell growth medium EGM-2
MV BulletKit. Treatments were as follows: conditioned media from
U373 GBM cells left untreated or treated with 100 μM TMZ for
72 hours were collected. The MTT test was performed on the two
HUVEC primary cultures in the presence of these 100% condi-
tioned media, a mixture of conditioned medium, and HUVEC
EGM-2 MV BulletKit medium in various proportions ranging from
90% U373 conditioned medium + 10% endothelial cell medium to
10% U373 conditioned medium + 90% endothelial cell culture
medium. As U373 cells are cultured in minimum essential medium
supplemented with 5% FCS, minimum essential medium + 5%
FCS-treated cells were included as an internal control.
The IC50 value, defined as the concentration that reduces the
global cell growth of 50%, was calculated with the following formula:
IC50 = (X2 − X1) × (50 − Y1) / (Y2 − Y1)) + X1, where X1 and X2 are
the higher and lower used concentrations, respectively, that borders
the concentration that reduces the global cell growth of 50% and Y1
and Y2 are the mean percentages of viable cells at the X1 and X2 con-
centrations, respectively.
In Vivo Orthotopic Xenografts
In vivo orthotopic xenografts of human Hs683 and U373 GBM
cells in nude mice were obtained as described previously [23,24,30,31].
Briefly, 50 μl of serum-free culture medium containing 100,000 GBM
cells were stereotactically injected into the brain of nude mice. All mice
(6-week-old female nu/nu mice; 21 to 23 g; Iffa Credo, Charles Rivers,
Arbresle, France) of a given experiment have Hs683 or U373 GBM
cells stereotactically implanted into the brain on the same day. Each
experimental group contained 11 mice. All the in vivo experiments de-
scribed in the present study were performed based on Authorization
#LA1230509 of the Animal Ethics Committee of the Federal Depart-
ment of Health, Nutritional Safety, and the Environment (Belgium).
In Vivo Determination of Tumor Neoangiogenesis
Each mouse receiving a GBM orthotopic xenograft underwent
euthanasia (in a CO2 atmosphere during 5 min) for ethical reasons
when it had lost 20% of its body weight compared to the day of
tumor grafting. The brain was removed from the skull, fixed in buff-
ered formalin for 5 days, embedded in paraffin, and then cut into
5-μm-thick sections. Resulting histology slides were stained with
hematoxylin and eosin for blood vessel counts. To quantify the level
of angiogenesis, a grid was used to determine the surface area of blood
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vessels in brain sections as reported previously [31,32]. Antiangiogenic
effects were analyzed in two distinct GBM models U373 (Figure 1C)
and Hs683 (Figure 1D) with and without treatment with TMZ. The
types of blood vessels taken into account are illustrated in Figure 2A.
A minimum of five fields at a G×400 magnification were analyzed per
histologic slide and two slides were analyzed per tumor. Thus, a mini-
mum total of 10 histologic fields per tumor were analyzed.
In Vitro Determination of HUVEC Capillary Networking
When cultured on Matrigel, HUVECs form capillary-like net-
works [31]. An amount of 800 μl of cold Matrigel was allowed to
set at 37°C for 10 minutes in a 3-cm Petri dish. The HUVECs growing
as primocultures in 25-mm2 flasks (Nunc, VWR, Leuven, Belgium)
were trypsinized, counted, and resuspended in the following culture
media: control medium was composed of 90% untreated U373 condi-
tioned medium mixed with 10% EGM medium; treated medium was
composed of 90% conditioned medium of TMZ-treated U373 cells
mixed with 10% EGM medium. U373 conditioned media were pre-
pared as detailed above. A total of 250,000 HUVECs were seeded
onto the matrix for each experiment conducted in duplicate. Formation
of capillary networks was observed during 24 hours by means of a
computer-assisted stereomicroscope (Olympus SZ-40; Omnilabo SA,
Antwerp, Belgium).
Protein Expression Measurements
Western blot analyses were performed as detailed previously [29,33].
Briefly, 40 μg of denaturated protein extracts was loaded in a poly-
acrylamide gel. After electrophoresis, proteins were transferred onto
a polyvinylidene fluoride membrane. To avoid aspecific binding of
the antibodies, membranes were first blocked in a 5% milk or BSA
buffer for 1 hour. The proteins were then detected by overnight in-
cubation at 4°C with the following primary antibodies: anti–HIF-1α
(dilution of 1:200; Abcam, Cambridge, UK), anti–ID-1 and –ID-2
(both at a dilution of 1:400; Santa Cruz, Heidelberg, Germany),
anti-cMyc (dilution of 1:400; Santa Cruz), and antitubulin (dilution
of 1:10,000; Abcam). Secondary antibodies were purchased from
Figure 1. TMZ in GBM models in vivo. (A) Intravenous TMZ treatment of immunocompromised mice bearing orthotopic xenografts of
human U373 cells. The black symbols illustrate the survival of control (untreated) groups, whereas the open symbols show the groups
treated i.v. with 40 mg/kg TMZ three times a week for three consecutive weeks, with the treatment starting on the 14th day after tumor
graft. The two pairs of circles versus squares represent two independent experiments performed 6 months apart. (B) The legend is
identical to that of (A), but the mice were treated for four (circles) or five (squares) consecutive weeks instead of three consecutive
weeks. (C) Oral TMZ treatment of immunocompromised mice bearing orthotopic xenografts of human U373 cells. The black symbols
illustrate the control (untreated) group, whereas the open symbols show the group treated with 80 mg/kg TMZ three times a week for
five consecutive weeks, with treatment starting on the 14th, 28th, 42nd, or 56th day after tumor graft. (D) Intravenous TMZ treatment
(40 mg/kg) of immunocompromised mice bearing orthotopic xenografts of human Hs683 cells. The black symbols illustrate the control
(untreated) group, whereas the open symbols show the group treated with 40 mg/kg TMZ three times a week for three consecutive
weeks, with the treatment starting on the 7th day after tumor graft. The two pairs of circles versus squares represent two independent
experiments performed at 6 months apart.
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Pierce (PerbioScience, Erembodegem, Belgium). Control experiments
included the omission of the incubation step with the primary anti-
bodies (negative control). Tubulin immunoblot analysis was then per-
formed on each membrane to assess the integrity and quantity of the
extracts. Western blots were developed using the Pierce Supersignal
Chemiluminescence system.
Statistical Analyses
Survival analyses were carried out by means of Kaplan-Meier
curves and Gehan’s generalized Wilcoxon test. Statistical comparisons
between control and treated groups were established by carrying out
the Kruskal-Wallis test (a nonparametric one-way analysis of variance)
or the Mann-Whitney test (in the case of two groups). All statistical
analyses were undertaken using Statistica (Statsoft, Tulsa, OK).
Results
Investigation of the Duration of TMZ Treatment on the
Survival of U373 and Hs683 Human GBM Orthotopic
Xenograft-Bearing Immunodeficient Mice
The U373 model is of astroglial origin and displays weak if any
sensitivity to proapoptotic cytotoxic drugs [30], whereas the Hs683
model is of oligodendroglial origin [30] and is sensitive to proapoptotic
drugs [30]. Both dramatically invade the brain parenchyma, and sur-
gery has been demonstrated to be of limited therapeutic benefit in the
U373 GBM model [34].
At a dosage of 40 mg/kg i.v. three times a week (Monday, Wednesday,
and Friday) for three consecutive weeks which displayed no toxicity
to mice (data not shown), TMZ (open symbols) did not significantly
increase (P > .05) the survival of U373-bearing mice compared to
controls (Figure 1A, black filled symbols). The two pairs of symbols:
circles versus squares represent two independent experiments per-
formed 6 months apart. Increasing the length of TMZ treatment
(40 mg/kg i.v.) to three times a week for 4 weeks resulted in a weak
but statistically significant increase in survival time (P < .05; Figure 1B,
open circles). However, increasing further the length of TMZ treatment
(40 mg/kg i.v.) to three times a week for 5 weeks markedly and sig-
nificantly increased survival times in U373-bearing mice (P < .01;
Figure 1B, open squares). Therapeutic benefits were also seen in the
U373 GBM model when TMZ was administered orally at 80 mg/
kg three times a week for five consecutive weeks, with marked im-
provements in survival time when the compound was administered
for the first time on the 14th as opposed to the 56th day after tumor
graft (Figure 1C).
The higher sensitivity of Hs683 to cytotoxic drugs compared to
the U373 GBM model [30] was also observed here with respect
Figure 2. Impact of TMZ administration on angiogenesis in GBMs. (A) Aa shows the typical morphologic and infiltrative characteristics of
the Hs683 tumor (T) in the excised brains of mice (HE indicates G×40; NB, normal brain tissue). Ab illustrates blood vessels in this tumor
(black arrows, HE; upper panel, G×100; lower panel, G×400). The grid was used at G×400 to determine the area covered by blood
vessels in the tumor field. Ex vivo quantitative data on percent surface area attributable to blood vessels are presented in Ac for Hs683
and U373 control and TMZ-treated tumors excised from experiments defined in Figure 1, D and C , respectively. Results for excised
U373 tumor relate to TMZ treatment starting on day 56 after tumor graft (Figure 1C , open circles). Results for excised Hs683 tumor
relate to TMZ treatment starting on day 7 after tumor graft (Figure 1D, open symbols). (B) The effects of TMZ treatment on the overall
growth of three different GBM cell cultures, namely, Hs683, T98G, and U373. Phase-contrast pictures of the three GBM cell lines left
untreated or treated for 7 hours for five consecutive days with 100 μM TMZ (pictures taken 7 days after the last treatment).
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to TMZ, as evidenced by a comparison of the data presented in
Figure 1, D (Hs683) and A (U373). Mice bearing Hs683 xeno-
grafts were also treated with 40 mg/kg i.v. three times a week for
3 weeks.
Characterization of the In Vivo TMZ-Induced Effects
on Angiogenesis in U373 and Hs683 Human GBM
Orthotopic Xenografts
The levels of angiogenesis were evaluated by determining blood
vessel surface area per field on histologic slides as detailed previously
[31] and as illustrated in Figure 2Ab in the case of Hs683 GBM. For
this analysis, brain samples were taken from animals implanted with
U373 or Hs683 GBM and treated, respectively, as detailed in Fig-
ure 1, C (control versus TMZ 80 mg/kg p.o., 3i × 5w from 14 to
56 days after graft) and D (control versus TMZ 40 mg/kg i.v., 3i ×
5w from 7 days after graft). A significant decrease in angiogenesis was
found in U373 tumor samples when the TMZ treatment started on
day 56 (Figure 2Ac) after tumor graft, whereas this was not the case
if the treatment began earlier (data not shown). By contrast, clinical
outcome (in survival) has been shown to be more improved when
TMZ treatment started earlier (Figure 1C ). This apparent discrep-
ancy between the therapeutic benefits and the antiangiogenic effects
of TMZ treatment could, however, be explained, at least partly, by
the shorter time lapse between the end of TMZ treatment and the
time of euthanasia for analysis when treatment started on day 56
(median time, ∼50 days) than the time lapse of the other groups (me-
dian time for the group beginning treatment on day 14, ∼170 days).
For those later, angiogenesis could have reincreased after TMZ treat-
ment. This hypothesis was further re-enforced with the significant
decrease in angiogenesis obtained in the case of the more aggressive
and shorter-lived Hs683 mouse model (Figure 2Ac) for which the
delay between the last TMZ administration and euthanasia is quite
short (median time, 12 days). Taken together, these data suggest that
TMZ could act as an antiangiogenic compound in vivo.
Effects of TMZ on the Growth Characteristics of Human
U87, T98G, U373, and Hs683 GBM Cell Lines In Vitro
In vitro IC50 inhibitory growth values for TMZ after 3 days of
culture were 472 ± 14 μM for U87, 118 ± 3 μM for U373, 634 ±
23 μM for T98G, and 719 ± 12 μM for Hs683 GBM cells. These
Figure 3. Western blot analyses of the expression levels of HIF-1α and ID2 in Hs683, U373, T98G, and U87 GBM cell lines. Cells were
treated for 7 hours for five consecutive days with 100 μM TMZ or left untreated. Protein extracts were collected on days 3, 5, and 7 after
the last TMZ treatment. Tubulin blots were used to assess equal loading in each experiment.
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data are in accordance with those reported by Fisher et al. [22] who
observed that a TMZ dose-related decrease in U251 and U87 GBM
cell numbers was evident at a TMZ concentration of 200 μM, which
became evident on day 6 and peaked after 8 days with a 3.5-fold re-
duction in cell viability.
U87, U373, T98G, and Hs683 GBM cells were treated in vitro in
a chronic manner with 100 μM TMZ. The drug was added to the
culture media each day for 7 hours (after that, the media were re-
placed with fresh medium without drug for 17 hours) for five con-
secutive days, and protein analyses were performed on the 3rd, 5th,
and 7th days that followed the 5th TMZ administration to the GBM
culture media (Figures 3 and 4). The morphologic illustrations in
Figure 2B show that a treatment of 5 × 100 μM TMZ (with an ob-
servation 7 days after the 5th TMZ administration) did not impair
T98G cell population growth, slightly impaired U87 (data not
shown) and Hs683 cell population growth, and moderately impaired
U373 cell population growth. These data are in accordance with
those reported by Kanzawa et al. [10] who observed that 100 μM
TMZ impaired cell growth and caused cell cycle arrest in the G2/M
phase in U373 GBM cells but not in T98G cells. Thus, the in vitro
5 × 100 μM treatment adopted here for four distinct human GBM cell
lines slightly, if any, impaired their growth characteristics. This proto-
col was then used to investigate whether TMZ was able to modify the
expression levels of various key factors implicated in tumor angio-
genesis as detailed below.
Characterization of TMZ-Induced Antiangiogenic Effects in
Human U87, T98G, U373, and Hs683 GBM Cell Lines
When treating U87 and U251 GBM cells for 4 days with 100 μM
TMZ, Fisher et al. [22] observed a common up-regulation of 61 genes
in these two cell lines, with 14 of these genes being known to be
up-regulated by the transcription factor HIF-1α. Analyzing the data
provided by Fisher et al. [22] and our own previous results [23,24]
of the potential relationship between endoplasmic reticulum stress,
angiogenesis, and TMZ treatment in experimental GBMs and the data
emphasizing the antiangiogenic effects of TMZ in various GBM
models [18,19] or in GBM patients [17], we decided to investigate
the effects of TMZ on hypoxia-related and proangiogenic factors,
i.e., HIF-1α, ID-1, ID-2, and c-Myc. Cell lines were treated for
7 hours/day for 5 days with 100 μM TMZ or vehicle alone (controls)
as indicated above, and samples were analyzed 3, 5, and 7 days after
the last TMZ treatment.
Figure 4.Western blot analyses of the expression levels of ID-1 and c-Myc in Hs683, U373, T98G, and U87 GBM cell lines. Temozolomide
treatment, sample processings, and legends are similar to those of Figure 3.
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Temozolomide produced a marked and sustained decrease in HIF-
1α expression in the four GBM cell lines investigated (Figure 3A).
Positive controls obtained by treating cells with 100 μM CoCl2 for
4 hours showed a marked increase in HIF-1α expression level.
ID factors, a family of four proteins interfering with transcription
factors and preventing their activities, are implicated in the control of
differentiation and cell cycle progression during embryogenesis and
tumorigenesis but have also been shown to be major players in
angiogenesis control [35]. ID-1 and ID-3 are required for endothelial
cell proliferation, networking processes, and for endothelial precur-
sor recruitment [35,36]. ID-2 is an HIF-1α–inducible protein [37]
that exerts a major role in angiogenesis [35] as it functions as a master
regulator of VEGF expression [38]. Temozolomide treatment of the
four GBM cell lines led to a generally marked and sustained decrease
in ID-1 and ID-2 expressions (Figures 3B and 4A).
The c-Myc oncogene has been shown to be involved in the angiogenic
switch of tumors. This activity relates to modification in pro- versus
antiangiogenic factor expression [39,40] and to a deep involvement
in metabolic adaptation to hypoxia [41,42]. Although the proto-
oncoprotein c-Myc seems to be the diametric opposite of HIF-1α
in most processes, recent studies indicate that c-Myc is an integral
part of the HIFs/c-Myc molecular pathway in the hypoxic response.
It has been shown that HIFs engage with c-Myc by various mechanisms
to achieve oxygen homeostasis for cell survival [42]. Temozolomide,
which is a proautophagic agent, induced a significant and sustained
decrease in the expression of c-Myc (up to 7 days after final drug treat-
ment) in the four GBM cell lines (Figure 4B).
Characterization of TMZ-Induced Effects on Antiangiogenic
Factors in HUVEC Endothelial Cell Lines
When TMZ is provided to GBM patients, it will target not only
GBM cells but also a large set of cell types implicated in tumor
angiogenesis, including endothelial cells. As shown above, TMZ modi-
fies the expression levels of various angiogenic factors in GBM cells.
These changes could lead to modifications to the microenvironment of
tumor endothelial cells and thus to tumor angiogenesis. This hypothe-
sis was evaluated in vitro by analyzing the effects of GBM cell culture
supernatants on the global growth level of HUVEC cell lines. U373
GBM cells were treated for 72 hours with 100 μM TMZ or left un-
treated. The collected supernatants either neat or diluted with fresh
HUVEC culture medium in different proportions were incubated
with HUVEC endothelial cells and viability/proliferation assessed
using the colorimetric MTT assay. Conditioned media from untreated
U373 GBM cells induced a significant increase in the global growth
of the two different primary HUVEC cell lines CH14 and HTG06
compared to endothelial growth medium (Figure 5A). By contrast,
conditioned media from TMZ-treated U373 cells induced a signifi-
cant decrease in the overall growth of these two primary HUVEC
cell lines when compared to either endothelial cell culture medium
(reported as 100% global growth in Figure 5A) or to conditioned
media from untreated U373 cells. These results seem to indicate that
TMZ exerts a marked indirect antiangiogenic effect in vitro, which
may relate to the compound’s effects on the expression of the pro-
angiogenic factors studied above. Indeed, when TMZ is added alone
into the endothelial culture medium, no effects are observed either on
global growth or on capillary networking (data not shown).
As a further evaluation, the effects of the GBM conditioned me-
dium on the tubulogenesis of HUVECs were determined. Human
umbilical vein endothelium cells were first treated for 24 hours with
Figure 5. Temozolomide effects on HUVECs in vitro and in com-
bination with bevacizumab in vivo in GBMmodels. (A) Graphical rep-
resentation of the effects of GBM conditioned media, either from
U373 GBM cells treated with TMZ or left untreated, on the global
growth of HUVECs. These results were obtained with the MTT
assay. The percentage of viable HUVEC control cells was arbitrarily
reported as 100%. The gray zone corresponds to the SEM of the
control condition. The control condition was HUVECs cultured in
endothelial cell growth medium EGM-2 MV BulletKit. Minimum es-
sential medium, 5%, was the culture medium for U373 cells. CH14
and HTG06 were two independent batches of HUVECs. These were
cultured in mixtures of conditioned medium from U373 cells (either
untreated: CH14 and HTG06 “cond”; or treated with TMZ: CH14
and HTG06 “cond with TMZ”) and endothelial cell growth medium
EGM (x axis). Results are presented as mean ± SEM. (B) Typical
illustrations of the capillary networks formed by HUVECs when
cultured for 24 hours on Matrigel. Ba relates to HUVECs cultured
with 90% untreated U373 conditioned medium mixed with 10%
EGM medium. Bb relates to HUVECs cultured with 90% con-
ditioned medium of TMZ-treated U373 cells mixed with 10%
EGM medium. (C) Survival analysis graphs for the in vivo Hs683
orthotopic GBM model treated with either TMZ (open squares)
or bevacizumab (open diamonds) compounds alone or a combina-
tion of both drugs (open circles). Control groups are represented
by black circles. Temozolomide and bevacizumab were adminis-
tered separately or in combination at 40 mg/kg p.o. and 10 mg/
kg i.v., respectively, three times per week for three consecutive
weeks. Drug administration began 5 days after GBM cell grafting.
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the GBM conditioned media detailed previously and then evaluated
for capillary-like structure formation when seeded on a Matrigel
matrix in the same conditioned culture medium. Figure 5Ba illus-
trates the tubular network formed by HUVECs cultured with a
mixture of 90% untreated U373 conditioned medium and 10%
endothelial culture medium. Using the U373 cells conditioned me-
dium treated for 72 hours with 100 μM TMZ led to impairment
of the tubular networking abilities of HUVECs as illustrated in Fig-
ure 5Bb. The antiangiogenic effects of TMZ observed in vivo could
therefore be related to modifications in proangiogenic factor expres-
sion evidenced above in GBM cells in vitro.
Effects of Combining Bevacizumab and TMZ in Human
GBM Orthotopic Xenograft Models
The Hs683 GBM orthotopic model was used to evaluate the po-
tential of combining TMZ with bevacizumab, an antiangiogenic
antibody targeting VEGF approved for the treatment of specified
cancer indications [43].
Temozolomide and bevacizumab were administered individually or
in combination at 40 mg/kg p.o. (suboptimal doses) and 10 mg/kg i.v.,
respectively, three times per week for three consecutive weeks. Drug
administration began 5 days after GBM cell grafting. Temozolomide
alone significantly improved animal survival times in Hs683 model
(P = .002; Figure 5C ). Hs683 was also responsive to bevacizumab,
which had a more marked effect on animal survival times than TMZ
(P < .0006 compared to the control group). However, the combina-
tion of bevacizumab with TMZ improved significantly the therapeu-
tic benefits of TMZ or bevacizumab alone in this GBM model (P =
.0008 and P = .02, respectively; Figure 5C ). Similar experiment has
been conducted in a human primary culture–derived orthotopic GBM
model. Whereas this latter was highly responsive to temozolomide but
did not respond to bevacizumab alone, combination of both treat-
ment significantly (P < .001) improved the therapeutic benefits of
temozolomide (data not shown).
Discussion
In addition to the large set of mechanisms of action already iden-
tified for TMZ’s antitumor activities, the present study emphasizes
that the compound also exerts its effects by impairing angiogenic
processes. Indeed, it has been demonstrated in vitro in this study that
the overall growth of HUVEC endothelial cell was decreased and
capillary network formation impaired when these cells were treated
with conditioned culture media from GBM cells treated with TMZ
(Figure 5, A and B). Similar features have been recently observed
with the cdk inhibitor SNS-032 [44]. The effects observed with
TMZ could occur, at least partly, through a TMZ-induced decrease
in the expression levels of several proangiogenic factors as indicated
in Figures 3 and 4.
Hypoxia plays a major role in the induction and stimulation of
angiogenesis through transcription factors like HIF family members
or oncogenes like c-Myc. The present study shows that TMZ is able
to inhibit HIF-1α expression in GBM cells. HIF-1α belongs to a
heterodimeric transcription factor family composed of α and β sub-
units [45]. In general, angiogenesis is dependent on the accumula-
tion of HIFs [45]. HIF-1 is among the primary genes involved in
the homeostatic process, which can increase vascularization in hyp-
oxic areas such as localized ischemia and tumors [45]. Moreover, the
hypoxia-induced metabolic switch to the anaerobic regimen of cancer
cells involves the activation and interplay of HIF and c-Myc tran-
scription factors [41,42]. The proangiogenic activities of the latter
relate to induced expression and release of interleukin 1β [39], which
acts as proangiogenic factor, and decreasing thrombospondin-1 ex-
pression, which itself acts as an antiangiogenic factor [40]. Figure 4
reveals that TMZ induces a marked decrease in c-Myc expression in
GBM cells. Given the important role of c-Myc in the hypoxic me-
tabolism switch, it remains possible that the decrease in its expression
induced by TMZ treatment could impair cell survival in an adverse
hypoxic environment and induce autophagic processes which have
been well documented by Kanzawa et al. [10] in the case of TMZ
treatment of glioma.
Table 1. Review of the Studies Combining Antiangiogenic Approaches With TMZ Treatment in GBM Models.
Compound Properties Model Graft Effects References
TNP-470 Inactivates MetAP2 resulting in endothelial cell
cycle arrest; antiangiogenic




Human SF188 [VEGF−] and transfected
VEGF +
s.c. and i.c. ↓ TMZ tumor concentrations [48]
↓ TMZ tumor/plasma ratio in both s.c.
and i.c. models
↓ of microvessels [only in VEGF +]
SU-5416 VEGFR-2 inhibitor antiangiogenic Human SF188 transfected VEGF + s.c. and i.c. ↑ TMZ tumor/plasma ratio only in i.c.
models and not s.c.
[49]
↓ of microvessels
Thalidomide [THD] Immunomodulator [↓ TNF-α] sedative,
hypnotic antiangiogenic
Rat C6 i.c. THD +TMZ tumor growth <TMZ or
THD with ↑ apoptosis, ↓ bFGF and
VEGF by TMZ or THD
[18]
HIF-1α knockdown Antiangiogenic Human D54MG s.c. ↑ TMZ therapeutic benefit [46]
↑ cytotoxic effects of TMZ in vitro
under hypoxia
Vandetanib Anti-Tyr kinases VEGFR-2 and EGFR;
antiangiogenic




Sunitinib Anti-Tyr kinases [VEGFR1 VEGFR3, PDGFR,
stem cell factor receptor…]; antiangiogenic
Human SF188 transfected VEGF + s.c. ↑ TMZ tumor/plasma ratio vascular
normalization
[51]
Galectin-1 siRNA Decreases the unfolded protein response,
impairs VEGF maturation and secretion
Human Hs683 i.c. ↑ TMZ therapeutic benefit [24]
The principal property of each compound is underlined.
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It has been previously shown that TMZ increases the expression
levels of galectin-1 in gliomas [23,24]. Galectin-1 is a potent pro-
angiogenic factor [26] involved in the endoplasmic reticulum stress
response [24]. In fact, regulation of angiogenesis results from the fine
tuning of the balance between pro- and antiangiogenic factors [45].
Here, we have shown that TMZ induced a marked decrease in the
expression of a number of proangiogenic factors leading to antiangio-
genic effects, not only in vitro but also in vivo, as revealed in Figure 2,
A and B. Our results therefore support previous publications demon-
strating that conventional and metronomic TMZ treatments have
antiangiogenic properties [17–20]. However, it still remains possi-
ble to increase the therapeutic benefit of TMZ with antiangiogenic
approaches/compounds having different targets. This was previously
evidenced by decreasing galectin-1 expression [24], which impaired
VEGF maturation and secretion [23] and by knocking down HIF-1α
(Table 1) [46].
The present study shows that administering in combination TMZ
and bevacizumab to Hs683 orthotopic GBM-bearing mice markedly
delayed death in these animals compared to when each drug was ad-
ministered alone (Figure 4). All in vivo studies conducted to date
with TMZ in combination with antiangiogenic approaches for the
experimental treatment of glioma models are summarized in Table 1.
Therapeutic approaches combining antiangiogenic drugs such as
bevacizumab with cytotoxics have recently entered routine practice
for cancers in general [43,52]. For example, in the case of breast
cancer, bevacizumab exerts potent antiangiogeneic activities [53]
and potentiates paclitaxel antitumor effects [54]. The success of such
combinations could result from at least three different mechanisms
of action as emphasized by Kerbel [55]: 1) preventing nutrient sup-
ply for tumor cell repopulation, 2) normalization of tumor vascula-
ture leading to improved cytotoxic drug delivery inside the tumor,
and 3) increasing the antiangiogenic effects of the chemotherapeutic
agents themselves.
Owing to well-known abnormalities, tumor blood vessel walls are
leaky, leading to an increase in interstitial pressure, which in turn
interferes with the diffusion of therapeutic agents into the tumor.
Therefore, blood vessel normalization obtained with antiangiogenic
compounds could be associated with higher drug tumor/plasma ratios
as shown by Ma et al. [49] (Table 1) and recently by Zhou et al. [51]
(Table 1) in the case of TMZ in glioma model treatment. However, in
the case of brain tumors, blood vessel normalization could be linked
to the restoration of the blood-brain barrier (BBB) which could hin-
der the transendothelial diffusion of anticancer agents like TMZ. This
process has been evidenced in a human orthotopic glioma model
(Table 1) [50]. A better understanding of the resulting effects of such
combinations might be achieved when taking into account the tumor
models (s.c. versus orthotopic implantation) and/or the antiangiogenic
compounds used, which are characterized by different mechanisms of
action leading to either synergistic or negative effects. Combination
therapy of bevacizumab and a cytotoxic seems well tolerated and active
against recurrent malignant gliomas [28,43]. Bevacizumab may alter
the recurrence pattern of malignant gliomas by suppressing enhancing
tumor recurrence more effectively than it suppresses nonenhancing
infiltrative tumor growth [28]. However, Chamberlain [56] raises the
point why the use of irinotecan in combination with bevacizumab in a
phase 2 study [43] despite consideration of the extremely limited single-
agent activity of irinotecan in recurrent GBM.
Antiangiogenic compounds also seem to be promising in increasing
the therapeutic benefits of radiotherapy [57]. A phase 2 pilot study of
bevacizumab in combination with TMZ and regional radiotherapy for
the treatment of patients with newly diagnosed GBM recently reported
that toxicities were acceptable to continue enrollment and a preliminary
analysis of efficacy showed encouraging mean progression-free survival
[58]. “Pure” antiangiogenic drugs, such as bevacizumab, should re-
enforce the antiangiogenic effects of certain cytotoxics. For TMZ in
particular, we have demonstrated in the present study its antiangiogenic
properties in vitro and in vivo when used alone. Using the Web site
developed by the National Library of Medicine for the US National
Institutes of Health, the authors obtained information on eight clinical
trials being conducted with bevacizumab in combination with TMZ,
which are recruiting patients with GBMs including those newly diag-
nosed. Our present study further validates these approaches.
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